{"id":"NCT04974749","sponsor":"Takeda","briefTitle":"A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease","officialTitle":"An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of REPLAGAL® in Treatment-naïve Chinese Subjects With Fabry Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-05-01","primaryCompletion":"2024-01-03","completion":"2024-01-03","firstPosted":"2021-07-23","resultsPosted":"2024-10-08","lastUpdate":"2024-10-08"},"enrollment":20,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fabry Disease"],"interventions":[{"type":"BIOLOGICAL","name":"REPLAGAL","otherNames":["Agalsidase Alfa","TAK-675"]}],"arms":[{"label":"REPLAGAL","type":"EXPERIMENTAL"}],"summary":"The main aim of the study is to assess the safety of REPLAGAL. Study participants will receive REPLAGAL as an intravenous infusion every other week for 52 weeks. Participants will visit their study clinic many times throughout the study.","primaryOutcome":{"measure":"Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs)","timeFrame":"From start of study drug administration up to 14 days after end of treatment (EOT) [up to Week 54]","effectByArm":[{"arm":"REPLAGAL","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":12},"locations":{"siteCount":6,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/61031f84beb21d002a926063"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":20},"commonTop":["COVID-19","Cough","Pyrexia","Upper respiratory tract infection","Headache"]}}